# EDGAR Filing Document

**Accession Number:** 0001610618
**File Stem:** 0001610618-23-000005
**Filing Date:** 2023-2
**Character Count:** 7742
**Document Hash:** f21e5ec069b26962257119e348a3e5ee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001610618-23-000005.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001610618-23-000005

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230214

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cidara Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001610618
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 461537286
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36912
- **FILM NUMBER:** 23622683

**BUSINESS ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-752-6170

**MAIL ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** K2 THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20140611

?xml version="1.0" ? cdtx-20230214

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 14, 2023**

**Cidara Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36912** | **46-1537286** |
| **(State or Other Jurisdiction of<br>Incorporation or Organization)** | **(Commission File Number)** | **(I.R.S. Employer<br>Identification Number)** |

---

**6310 Nancy Ridge Drive, Suite 101**

**San Diego, California 92121**

**(858) 752-6170**

**(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, Par Value $0.0001 Per Share | CDTX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 8.01 Other Events.**

On February 14, 2023, Cidara Therapeutics, Inc. (the "Company") issued a press release announcing that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Title or Description** |
| 99.1 | <u>[Press release dated February 14, 2023.](ex9912023-02x14.htm)</u> |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Cidara Therapeutics, Inc.** | **Cidara Therapeutics, Inc.** |
| Date: February 14, 2023 | | /s/ Jeffrey Stein, Ph.D. |
| | | Jeffrey Stein, Ph.D. |
| | | President and Chief Executive Officer<br>(Principal Executive Officer) |

---

## Exhibit 99.1

**Exhibit 99.1**

![cdtxlogoa18.jpg](cdtxlogoa18.jpg)

**Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement**

SAN DIEGO, February 14, 2023 – Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq"), stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

The Company was first notified by Nasdaq on February 28, 2022, that its common stock had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. Nasdaq provided a 180-calendar day period following the date of the notice to regain compliance, after which the Company requested a hearing before the Nasdaq Hearings Panel (the "Panel"). On October 6, 2022, the Company attended a hearing before the Panel and presented its plan to regain compliance with the Minimum Bid Price Requirement and requested additional time within which to regain compliance. On October 18, 2022, the Panel granted the Company's request for continued listing pursuant to an extension, through February 27, 2023, to regain compliance.

The requested extension was granted by the Panel contingent on certain specified commitments, including that the Company would implement a reverse stock split of its common stock if it was otherwise unable to regain compliance with the Minimum Bid Price Requirement before expiration of the extension. On December 15, 2022, at a special meeting of stockholders, the stockholders of the Company approved a reverse split at a ratio between one-to-ten and one-to-twenty. A reverse split was not implemented given that, between January 25, 2023 and February 7, 2023, for a period of 10 consecutive trading days, the closing bid price of the Company's common stock was greater than $1.00 per share. On February 9, 2023, the Panel notified the Company that it had regained compliance with the Minimum Bid Price Requirement subject to a discretionary Panel Monitor until November 9, 2023. The Panel has deemed this matter closed.

**About Cidara Therapeutics**

Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company's portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara's proprietary Cloudbreak<sup>®</sup> platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

------

**INVESTOR CONTACT:**

Brian Ritchie

LifeSci Advisors

(212) 915-2578

britchie@lifesciadvisors.com

**MEDIA CONTACT:**

Patrick Bursey

LifeSci Communications

(203) 430-9545

pbursey@lifescicomms.com